| Today’s Big NewsJan 17, 2024 |
| By Annalee Armstrong,Gabrielle Masson Biotech executives are reaching into their bag of tricks and coming up with wild ways to access capital. It's not enough to have M&A in mind or plan for an IPO. You need to have both underway, just in case. |
|
|
|
By Fraiser Kansteiner Pfizer knows it had a bad year in 2023. Speaking to reporters at the 2024 J.P. Morgan Healthcare Conference on Monday, the company’s CEO, Albert Bourla, spoke bluntly about the hits the company took, and he acknowledged the underperformance of certain key launches. |
By Annalee Armstrong,Gabrielle Masson Biotech executives are reaching into their bag of tricks and coming up with wild ways to access capital. It's not enough to have M&A in mind or plan for an IPO. You need to have both underway, just in case. |
By Angus Liu Nearly all top cancer drugmakers have struck deals in the sizzling antibody-drug conjugate field—but not Novartis. On Monday, the Swiss pharma’s CEO Vas Narasimhan explained how he's resisted the temptation. |
By Annalee Armstrong Eli Lilly CEO David Ricks, speaking to the slow and steady progress that brought tirzepitide to the world, says the Indianapolis pharma is now ready to open up the chocolate factory. |
By Angus Liu While some Merck & Co. investors may still get the heebie-jeebies when thinking about Keytruda’s patent cliff in 2028, but the company’s CEO Rob Davis now thinks “it’s just another year.” |
By Max Bayer Takeda cemented itself as a player in the immunology arena when it bought Nimbus' TYK2 inhibitor a year ago, putting it toe-to-toe against Bristol Myers Squibb. Now, the Japanese pharma has detailed just how the drug landed in its pipeline. |
By Annalee Armstrong The overall deal flow in biopharma tapered off in 2023 but the big companies sure know what they want (what they really, really want), according to a new report from J.P. Morgan. |
By Gabrielle Masson,Annalee Armstrong,Max Bayer As the biotech industry attempts to claw its way out of a brutal bear market, investors are starting to pull their punches in preference for more sure bets. |
By Annalee Armstrong Sometimes, you have to act while the tea is hot. For Roivant CEO Matt Gline, that meant dealing out Telavant to Roche for $7.1 billion last year, even if he wasn’t quite ready to let the vant company go. |
By Angus Liu Bluebird bio’s 40% list-price premium for Lyfgenia compared with Vertex and CRISPR Therapeutics’ sickle cell disease drug surprised many industry watchers last month. But bluebird CEO Andrew Obenshain argues the prices for the gene therapy rivals shouldn’t be compared directly. |
By Angus Liu As one of the first Big Pharmas to embrace antibody-drug conjugates, Roche plans to bet more on the popular cancer modality, Global Head of Pharma Partnering James Sabry, Ph.D., told Fierce. But biotechs looking for a Roche alliance must first meet an invisible bar. |
By Angus Liu Despite its recent $43 billion acquisition of Seagen, Pfizer is still on the lookout for deals centered on antibody-drug conjugates, Pfizer’s newly minted chief oncology officer Chris Boshoff, Ph.D., said in an interview. But the company isn’t considering large buyouts at the moment. |
By Max Bayer Novartis’ R&D chief Fiona Marshall, Ph.D., says the company has been “pretty aggressive and active” in neuroscience-focused business development, looking for a boost to one of the company’s four key therapeutic pillars. |
By Max Bayer Flagship CEO Noubar Afeyan says there's more work to be done before the firm starts making deals in China, two months after opening an Asia-Pacific hub in Singapore. The company launched its first U.K.-based biotech, Quotient Therapeutics, at the end of 2023. |
By Conor Hale We’ve compiled the biggest medtech news coming out of the 2024 J.P. Morgan Healthcare Conference, from in and around San Francisco and all points beyond. |
By Max Bayer Sanofi CEO Paul Hudson did not rule out further business development related to Pompe disease despite the FTC's challenge of its deal with Maze Therapeutics. The pharma company's concern is that the latest action could result in the death of the program due to a lack of funding. |
By Annalee Armstrong The biotech industry has a love-hate relationship with the J.P. Morgan Healthcare Conference in San Francisco. Every year, thousands gather on the Golden Gate City and battle rain, hail, floods, what have you, just to make billion-dollar deals. |
| |
|
